Traditional Chinese medicinal composition with anti-tumor activity

Abstract

The invention discloses a traditional Chinese medicinal composition with anti-tumor activity. The composition is prepared from the following bulk drugs in parts by weight: 30-60 parts of ginseng, 20-40 parts of radix ophiopogonis, 30-50 parts of oldenlandia diffusa, 10-40 parts of sculellaria barbata, 10-20 parts of rhizoma arisaematis, and 10-30 parts of curcuma zedoary. According to the traditional Chinese medicinal composition, the traditional Chinese medicinal prescription is screened by adopting the theory of treatment based on syndrome differentiation according to traditional Chinese medical theory, and the traditional Chinese medicinal composition is scientific and reasonable in proportion. Experiment results indicate that the traditional Chinese medicinal composition has a good effect in inhibiting tumor cell growth and promoting tumor cell apoptosis, has a strong killing effect on multiple malignant cells, and is wide in application range; pains of a tumor patient can be remarkably reduced, the living period can be prolonged, and the life quality of the patient can be improved. Long-term experiments and researches indicate that the traditional Chinese medicinal composition is high in safety and low in toxic or side effect, and can be developed into a novel anti-tumor medicine.

Description

technical field [0001] The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition with antitumor activity, and belongs to the technical field of medicine and pharmacy. Background technique [0002] Tumor has become the number one killer threatening human survival in the 21st century, with an average of more than 6 million people dying of various tumor diseases every year. China is one of the countries with a high incidence of cancer in the world. There are more than 2 million new cancer patients every year, accounting for 20% of the global total. There are more than 4 million cancer patients, and there is a rapid growth trend every year. Clinically, the current drugs for treating tumors mainly include chemical drugs. However, due to the high toxicity of chemotherapy drugs, they can not selectively kill white blood cells, lymphocytes and other human immune cells while killing tumor cells. As a result, patie...

AI Technical Summary

Problems solved by technology

Clinically, the current drugs for treating tumors mainly include chemical drugs. However, due to the high toxicity of chemotherapy drugs, they can not selectively kill white blood cells, lymphocytes and other human immune cells while killing tumor cells. As a result, patients often suffer from autoimmune diseases. Complicated infection due to low ability, large adverse reactions in patients, long course of treatment, high cost, and great limitations in clinical use

Images